Pyrazolylthiazole as Δf508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles

Journal of Medicinal Chemistry

Volumn 53, Issue 9, 2010, Pages 3772-3781

  Ye, Long ^a   Knapp, John M ^a   Sangwung, Panjamaporn ^b   Fettinger, James C ^a   Verkman, A S ^b   Kurth, Mark J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; AMIDE; ESTER; PHENYLALANINE DERIVATIVE; PHENYLALANINE RESIDUE 508; PYRAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508;

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; GENE DELETION; HYDROPHILICITY; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; SYNTHESIS; X RAY CRYSTALLOGRAPHY; DRUG EFFECT; FRAMESHIFT MUTATION; HUMAN; MOLECULAR LIBRARY; STATIC ELECTRICITY;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FRAMESHIFT MUTATION; HUMANS; PYRAZOLES; SMALL MOLECULE LIBRARIES; STATIC ELECTRICITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 77952018949     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100235h     Document Type: Article

References (29)

1. Bobadilla, J. L.; Macek, M; Fine, J. P.; Farrell, P. M. Cystic fibrosis: a worldwide analysis of CFTR mutations. Correlation with incidence data and application to screening Hum. Mutat. 2002, 19, 575-606
2. Snouwaert, J. N.; Brigman, K. K.; Latour, A. M.; Malouf, N. N.; Boucher, R. C.; Smithies, O.; Koller, B. H. An animal model for cystic fibrosis made by gene targeting Science 1992, 257, 1083-1088
3. Sharma, M.; Benharouga, M.; Hu, W.; Lukacs, G. L. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in postendoplasmic reticulum compartments J. Biol. Chem. 2001, 276, 8942-8950
4. Skach, W. R. Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator Kidney Int. 2000, 57, 825-831
5. Zeiher, B. G.; Eichwald, E.; Zabner, J.; Smith, J. J.; Puga, A. P.; McCray, P. B., Jr.; Capecchi, M. R.; Welsh, M. J.; Thomas, K. R. A mouse model for the delta F508 allele of cystic fibrosis J. Clin. Invest. 1995, 96, 2051-2064
6. Pedemonte, N; Lukacs, G. L.; Du, K.; Caci, E.; Zegarra-Moran, Ol.; Galietta, L. J. V.; Verkman, A. S. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening J. Clin. Invest. 2005, 115, 2564-2571
7. Yoo, C. L.; Yu, G. J.; Yang, B.; Robins, L. I.; Verkman, A. S.; Kurth, Mark J. 4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing Bioorg. Med. Chem. Lett. 2008, 18, 2610-2614
8. Yu, G. J.; Yoo, C. L.; Yang, B.; Lodewyk, M. W.; Meng, L.; El-Idreesy, T. T.; Fettinger, J. C.; Tantillo, D. J.; Verkman, A. S.; Kurth, M. J. Potent s- cis -locked bithiazole correctors of ΔF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy J. Med. Chem. 2008, 51, 6044-6054
9. Tanitame, A.; Oyamada, Y.; Ofuji, K.; Terauchi, H.; Kawasaki, M.; Wachi, M.; Yamagishi, J. Synthesis and antibacterial activity of a novel series of DNA gyrase inhibitors: 5-[(E)-2-arylvinyl]pyrazoles Biol. Med.Chem. Lett. 2005, 15, 4299-4303
10. Li, Q.; Zu, Y.; Shi, R.; Yao, L.; Fu, Y.; Yang, Z.; Li, L. Synthesis and antitumor activity of novel 10-substituted camptothecin analogues Bioorg. Med. Chem. 2006, 14, 7175-7182
11. Keter, F. K.; Nell, M. J.; Guzei, I. A.; Omondi, B.; Darkwa, J. Anticancer activities of bis(pyrazol-1-ylthiocarbonyl)disulfides against HeLa cells J. Chem. Res. 2009, 322-325
12. Dai, H.; Li, Y.; Du, D.; QX.; Zhang, X.; Yu, H.; Fang, J. Synthesis and biological activities of novel pyrazole oxime derivatives containing a 2-chloro-5-thiazolyl moiety J. Agric. Food Chem. 2008, 56, 10805-10810
13. De MorF. F.; Chen, J. J.; Doherty, E. M.; Hitchcock, S.; Huang, Q.; Kim, J. L.; Liu, G.; Nixey, T.; Paras, N. A.; Petkus, J.; Retz, D. M.; Smith, A. L.; Tasker, A.; Zhu, J. Preparation of nitrogen-containing bicyclic heteroaryl compounds as antitumor agents. PCT Int. Appl. WO 2007076092 A2 20070705, 2007.
14. Knorr, L. Action of ethyl acetoacetate on phenylhydrazine. I Ber. 1883, 16, 2597-2599
15. Elguro, J. Pyrazoles and their benzo derivatives Compr. Heterocycl. Chem. 1984, 5, 167-303
16. Makino, K.; Kim, H. S.; Kurasawa, Y. Synthesis of pyrazoles J. Heterocycl. Chem. 1998, 35, 489-497
17. Silva, V. L. M.; Silva, A. M. S.; Pinto, D. C. G. A.; Cavaleiro, J. A. S.; Elguero, J. 3(5)-(2-Hydroxyphenyl)-5(3)-styrylpyrazoles: Synthesis and Diels-Alder transformations Eur. J. Org. Chem. 2004, 4348-4356
18. Heller, S. T.; Natarajan, S. R. 1,3-Diketones from acid chlorides and ketones: A rapid and general one-pot synthesis of pyrazoles Org. Lett. 2006, 8, 2675-2678
19. Yanborisov, T. N.; Zhikina, I. A.; Andreichikov, Yu. S.; MilyutA. V.; Plaksina, A. N. Synthesis and pharmacological activity of heteroylpyruvic acids and their derivatives Khim.-Farm. Zh. 1998, 32, 26-28
20. Dinges, J.; Akritopoulou-Zanze, I.; Arnold, L. D.; Barlozzari, T.; Bousquet, P. F.; Cunha, G. A.; Ericsson, A. M.; Iwasaki, N.; Michaelides, M. R.; Ogawa, N.; Phelan, K. M.; Rafferty, P.; SowT. J.; Stewart, K. D.; Tokuyama, R.; Xia, Z.; Zhang, H. Q. Hit-to-lead optimization of 1,4-dihydroindeno[1,2- c ]pyrazoles as a novel class of KDR kinase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 4371-4375
21. Yang, H.; Shelat, A. A.; Guy, R. K.; Gopinath, V. S.; Ma, T.; Du, K.; Lukacs, G. L.; Taddei, A.; Folli, C.; Pedemonte, N.; Galietta, L. J. V.; Verkman, A. S. Nanomolar affinity small molecule correctors of defective ΔF508-CFTR chloride channel gating J. Biol. Chem. 2003, 278, 35079-35085
22. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development Adv. Drug. Delivery Rev. 1997, 23, 3-25
23. Kerns, E. H.; Di, L. Physicochemical profiling: overview of the screens Drug Discovery Today 2004, 1, 343-348
24. Wang, J.; Krudy, G.; Hou, T.; Zhang, W.; Holland, G.; Xu, X. Development of reliable aqueous solubility models and their application in druglike analysis J. Chem. Inf. Model. 2007, 47, 1395-1404
25. Dressman, J. B.; Thelen, K.; Jantratid, E. Towards quantitative prediction of oral drug absorption Clin. Pharmacokinet. 2008, 47, 655-667
26. Braumann, T. Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships J. Chromatogr. 1986, 373, 191-225
27. Vrakas, D.; Tsantili-Kakoulidou, A.; Hadjipavlou-Litina, D. Exploring the consistency of log P estimation for substituted coumarins QSAR Comb. Sci. 2003, 22, 622-629
28. Galietta, L. J.; Haggie, P. M.; Verkman, A. S. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities FEBS Lett. 2001, 499, 220-224
29. Hantzsch, A. Thiazoles from thiamides Justus Liebigs Ann. Chem. 1889, 250, 257-73